- Home
- RXST
RXST
RxSight Inc.
as 02-21-2025 4:00pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Upcoming Earnings Alert:
Get ready for potential market movements as RxSight Inc. RXST prepares to release earnings report on 25 Feb 2025.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $58.13 | AVG Volume (30 days): | 492.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.29 - $66.54 | Next Earning Date: | 02-25-2025 |
| Revenue: | $128,293,000 | Revenue Growth: | 67.52% |
| Revenue Growth (this year): | 60.3% | Revenue Growth (next year): | 34.65% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maniar Shweta | RXST | Director | Jan 22 '25 | Sell | $30.87 | 3,519 | $108,618.16 | 7,383 | |
| Corley Jesse Anderson | RXST | Director | Jan 15 '25 | Buy | $31.16 | 3,210 | $100,004.19 | 1,443 | |
| Goldshleger Ilya | RXST | See remarks | Nov 29 '24 | Sell | $46.08 | 3,105 | $143,078.40 | 42,246 | |
| Maniar Shweta | RXST | Director | Nov 26 '24 | Sell | $45.88 | 3,782 | $173,518.16 | 7,383 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025
Simply Wall St.
21 days ago
Insider Stock Buying Reaches US$1.83m On RxSight
TipRanks
a month ago
RxSight price target lowered to $43 from $66 at Needham
MT Newswires
a month ago
RxSight Reports Preliminary Q4 Revenue, Issues 2025 Outlook
GlobeNewswire
a month ago
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
GlobeNewswire
2 months ago
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
MT Newswires
2 months ago
RxSight Shares Fall After Stifel Downgrade
Insider Monkey
2 months ago
Do You Believe in the Long-Term Growth Potential of RxSight (RXST)?
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.